Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

Inclusion Criteria: * Patients fulfilling one or more of the following criteria will be considered to have resistant DME after at least 3 consecutive monthly anti VEGF injections in the previous 6 months: * Central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT). * Reduction of retinal thickness by less than 10% of baseline retinal thickness. * Suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart) and patients with recent onset central retinal vein occlusion less than 3 months. Exclusion Criteria: * Previous intraocular surgery (except cataract surgery done more than 6 months before the study). * Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration. * Previous laser photocoagulation. * Intravitreal injection of triamcinolone acetonide. * Prior ocular inflammation. * The presence of retinal degeneration. * Patients who didnot complete 6 months of follow up